NO970625L - 17q-koblete bryst- og ovariekreft mottagelighetsgener - Google Patents

17q-koblete bryst- og ovariekreft mottagelighetsgener

Info

Publication number
NO970625L
NO970625L NO970625A NO970625A NO970625L NO 970625 L NO970625 L NO 970625L NO 970625 A NO970625 A NO 970625A NO 970625 A NO970625 A NO 970625A NO 970625 L NO970625 L NO 970625L
Authority
NO
Norway
Prior art keywords
ovarian cancer
breast
human
mutations
gene
Prior art date
Application number
NO970625A
Other languages
English (en)
Other versions
NO970625D0 (no
Inventor
Mark H Skolnick
David E Goldgar
Yoshio Miki
Jeff Swenson
Alexander Kamb
Keith D Harshman
Donna M Shattuck-Eidens
Sean V Tavtigian
Roger W Wiseman
Andrew P Futreal
Original Assignee
Myriad Genetics Inc
Us Health
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27575337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO970625(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/483,554 external-priority patent/US5747282A/en
Priority claimed from US08/487,002 external-priority patent/US5710001A/en
Application filed by Myriad Genetics Inc, Us Health, Univ Utah Res Found filed Critical Myriad Genetics Inc
Publication of NO970625D0 publication Critical patent/NO970625D0/no
Publication of NO970625L publication Critical patent/NO970625L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

Foreliggende oppfinnelse vedrører generelt området human genetikk. Spesielt vedrøres fremgangsmåter og materialer benyttet til å isolere og detektere et human bryst- og ovariekreft predisponeringsgen (BRCA1), noen mutantalleler av hvilket forårsaker mottagelighet for kreft, særlig bryst- og ovariekreft. Mer spesielt vedrøres kjønnscelle-mutasjoner i BRCA1 genet og deres bruk i diagnose av predisponering av human bryst- og ovariekreft. Ytterligere vedrører oppfinnelsen somatiske mutasjoner i BRCA1 genet i human bryst- og ovariekreft og deres anvendelse i diagnose og prognose av human bryst- og ovariekreft. I tillegg vedrøres somatiske mutasjoner i BRCA1 genet i andre humane kreftformer og deres bruk i diagnose og prognose av humane krefttyper. Oppfinnelsen vedrører også behandling av human kreft som har mutasjoner i BRCA1 genet inkludert genterapi, proteinerstatningsterapi og proteinetterligninger. Del beskrives videre screening av legemidler for kreftbehandling. Endelig beskrives screening av BRCA1 genet for mutasjoner, som er nyttig for diagnostisering av predisponering av bryst- og ovariekreft.
NO970625A 1994-08-12 1997-02-11 17q-koblete bryst- og ovariekreft mottagelighetsgener NO970625L (no)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28922194A 1994-08-12 1994-08-12
US30026694A 1994-09-02 1994-09-02
US30810494A 1994-09-16 1994-09-16
US34882494A 1994-11-29 1994-11-29
US40930595A 1995-03-24 1995-03-24
US48801195A 1995-06-07 1995-06-07
US08/483,554 US5747282A (en) 1994-08-12 1995-06-07 17Q-linked breast and ovarian cancer susceptibility gene
US08/487,002 US5710001A (en) 1994-08-12 1995-06-07 17q-linked breast and ovarian cancer susceptibility gene
PCT/US1995/010203 WO1996005307A2 (en) 1994-08-12 1995-08-11 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE

Publications (2)

Publication Number Publication Date
NO970625D0 NO970625D0 (no) 1997-02-11
NO970625L true NO970625L (no) 1997-04-14

Family

ID=27575337

Family Applications (2)

Application Number Title Priority Date Filing Date
NO970625A NO970625L (no) 1994-08-12 1997-02-11 17q-koblete bryst- og ovariekreft mottagelighetsgener
NO970626A NO970626L (no) 1994-08-12 1997-02-11 Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO970626A NO970626L (no) 1994-08-12 1997-02-11 Fremgangsmåte for å diagnostisere disponering for bryst- og ovariekreft

Country Status (15)

Country Link
EP (2) EP0705902B2 (no)
JP (1) JP3399539B2 (no)
CN (1) CN1159829A (no)
AT (2) ATE198623T1 (no)
AU (2) AU691331B2 (no)
CA (2) CA2196790C (no)
DE (2) DE69519834T3 (no)
DK (2) DK0699754T3 (no)
ES (2) ES2164136T5 (no)
FI (2) FI970515A7 (no)
GR (1) GR3035631T3 (no)
NO (2) NO970625L (no)
NZ (1) NZ291624A (no)
PT (2) PT699754E (no)
WO (2) WO1996005307A2 (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US6403303B1 (en) 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
US6130322A (en) * 1996-02-12 2000-10-10 Gene Logic, Inc. Coding sequences of the human BRCA1 gene
US6951721B2 (en) 1996-02-12 2005-10-04 Gene Logic Inc. Method for determining the haplotype of a human BRCA1 gene
US5654155A (en) * 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US5891857A (en) * 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
CA2262479A1 (en) 1996-08-02 1998-02-12 The Wistar Institute Of Anatomy And Biology Brca1 associated protein (bap-1) and uses therefor
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
EP1012577A4 (en) * 1996-12-03 2004-08-04 Michael R Swift PREDISPOSITION TO BREAST CANCER RELATED TO MUTATIONS AFFECTING THE LOCUS OF THE ATAXIA GENE TELANGIECTASIA
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
US6733966B1 (en) 1997-06-04 2004-05-11 Rijksuniversiteit Te Leiden Diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
EP1003779A1 (en) * 1997-07-07 2000-05-31 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US5994096A (en) * 1997-07-25 1999-11-30 Smithkline Beecham Corporation Regulator
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6177410B1 (en) 1997-12-05 2001-01-23 Vanderbilt University Therapeutic methods for prostate cancer
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002317247A1 (en) * 2001-06-13 2002-12-23 Centre National De La Recherche Scientifique (C.N.R.S.) Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications
FR2826012B1 (fr) * 2001-06-13 2003-09-26 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
FR2836919B1 (fr) * 2002-03-05 2004-07-09 Centre Nat Rech Scient Complexes moleculaires brca1/accalpha, applications diagnostiques et therapeutiques
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
KR20060123403A (ko) 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 ｄｎａ 손상 수복 억제제
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101037690B (zh) * 2006-03-16 2011-07-20 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007138355A1 (en) 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
CA2733597C (en) 2008-08-10 2019-02-26 Kuakini Medical Center Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity
ES2598178T5 (es) 2008-10-07 2023-12-26 Kudos Pharm Ltd Formulación farmacéutica 514
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
AU2010221721A1 (en) * 2009-02-06 2011-08-18 Yale University A SNP marker of breast and ovarian cancer risk
WO2011007145A1 (en) 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound as parp inhibitor
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN105525009B (zh) * 2016-01-26 2018-10-16 绍兴华因生物科技有限公司 检测杂合性brca1/2基因缺失的方法及所用引物
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113388680B (zh) * 2020-03-14 2023-07-04 复旦大学附属妇产科医院 上皮性卵巢癌靶点ret及其在诊断和治疗中的作用
KR102262529B1 (ko) * 2020-06-15 2021-06-09 연세대학교 산학협력단 Brca 변이성 난소암에 대한 진단 방법 및 이를 이용한 키트
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
IL301921A (en) 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20240366584A1 (en) 2021-06-21 2024-11-07 Tesaro, Inc. Combination treatment of cancer with a parp inhibitor and a lipophilic statin
KR20240125925A (ko) 2021-11-18 2024-08-20 아스트라제네카 유케이 리미티드 항체-약물 콘쥬게이트와 parp1 선택적 억제제의 조합
IL313661A (en) 2021-12-21 2024-08-01 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
TW202339805A (zh) 2021-12-28 2023-10-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物及atr抑制劑之組合
CN118434422A (zh) 2021-12-28 2024-08-02 阿斯利康(英国)有限公司 抗体-药物缀合物和rasg12c抑制剂的组合
IL315662A (en) 2022-03-16 2024-11-01 Astrazeneca Uk Ltd A scoring method for an anti trop2 antibody drug conjugate therapy
WO2023194530A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194528A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
WO2023194525A1 (en) 2022-04-07 2023-10-12 Astrazeneca Ab Combination therapy for treating cancer
IL317573A (en) 2022-06-15 2025-02-01 Astrazeneca Ab Combination therapy for cancer treatment
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
WO2024116094A1 (en) 2022-11-30 2024-06-06 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugates and dnmt inhibitors
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
TW202535479A (zh) 2023-12-05 2025-09-16 英商阿斯特捷利康英國股份有限公司 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合
TW202545525A (zh) 2024-01-19 2025-12-01 瑞典商阿斯特捷利康公司 包含ａｚｄ５３０５之藥物組成物
WO2026052764A1 (en) 2024-09-06 2026-03-12 Astrazeneca Uk Limited A scoring method for an anti-trop2 antibody drug conjugate therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
JPH05508307A (ja) * 1990-01-04 1993-11-25 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒトの結腸直腸ガンで欠失した遺伝子
ES2264239T3 (es) * 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
AU1236092A (en) * 1991-01-04 1992-08-17 Baylor College Of Medicine Tumor susceptible non-human animals
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU4645293A (en) * 1992-06-26 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The The met proto-oncogene and a method for predicting breast cancer progression
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
FI970514A0 (fi) 1997-02-07
ES2164136T3 (es) 2002-02-16
EP0699754A1 (en) 1996-03-06
GR3035631T3 (en) 2001-06-29
NO970626D0 (no) 1997-02-11
NZ291624A (en) 1998-07-28
AU3321695A (en) 1996-03-07
EP0699754B2 (en) 2009-08-12
FI970515A0 (fi) 1997-02-07
PT705902E (pt) 2002-05-31
DE69519834T2 (de) 2001-04-26
EP0705902B2 (en) 2008-08-06
JP3399539B2 (ja) 2003-04-21
FI970514A7 (fi) 1997-04-07
DK0699754T3 (da) 2001-02-26
DE69524182T2 (de) 2002-05-29
WO1996005308A1 (en) 1996-02-22
DE69524182D1 (de) 2002-01-10
NO970626L (no) 1997-04-14
NO970625D0 (no) 1997-02-11
CA2196790C (en) 2000-10-10
AU691958B2 (en) 1998-05-28
ATE198623T1 (de) 2001-01-15
DE69519834D1 (de) 2001-02-15
WO1996005307A2 (en) 1996-02-22
CA2196795C (en) 2001-04-03
CA2196790A1 (en) 1996-02-22
ES2154712T5 (es) 2009-12-14
ATE209660T1 (de) 2001-12-15
CA2196795A1 (en) 1996-02-22
CN1159829A (zh) 1997-09-17
EP0705902B1 (en) 2001-11-28
WO1996005307A3 (en) 1996-03-14
PT699754E (pt) 2001-04-30
DE69524182T3 (de) 2009-07-09
DE69519834T3 (de) 2010-04-01
AU3242895A (en) 1996-03-07
EP0699754B1 (en) 2001-01-10
ES2164136T5 (es) 2009-02-16
ES2154712T3 (es) 2001-04-16
AU691331B2 (en) 1998-05-14
FI970515A7 (fi) 1997-04-07
DK0705902T3 (da) 2002-03-11
EP0705902A1 (en) 1996-04-10
JP2002502227A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
NO970625L (no) 17q-koblete bryst- og ovariekreft mottagelighetsgener
NO970624L (no) In vivo mutasjoner og polymorfismer i det 17q-koblete bryst-og ovariekreft mottagelighetsgener
NO982785D0 (no) Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (en) Chromosome 13-linked breast cancer susceptibility gene
Truderung et al. Melanoma susceptibility: An update on genetic and epigenetic findings
Alimirzaie et al. Mutations in known and novel cancer susceptibility genes in young patients with pancreatic cancer
Bijlsma et al. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism.
Martin et al. Exclusion of PITX2 mutations as a major cause of CHARGE association
Wang et al. Braf mutations initiate the development of rat gliomas induced by postnatal exposure to N-Ethyl-N-nitrosourea
Wu et al. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas.
Haytural et al. Identification of a novel BRCA2 and CHEK2 ACGC haplotype in Turkish patients affected with breast cancer
Wan et al. Two variants of the human hepatocellular carcinoma‐associated HCAP1 gene and their effect on the growth of the human liver cancer cell line Hep3B
Venkateshwari et al. BRIP1/FANCJ mutation analysis in a family with history of male and female breast Cancer in India
Nilbert et al. Novel germline APC mutations in Swedish patients with familial adenomatous polyposis and Gardner syndrome
Tell-Marti et al. The p. R151c polymorphism in mc1r gene modifies the age of onset in spanish huntington’s disease patients
Feng et al. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2‐related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families
Espinós et al. Ala397Asp mutation of myosin VIIA gene segregating in a Spanish family with type-Ib Usher syndrome
Vile p53: a gene for all tumours?
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
MX9701076A (es) Metodo para diagnosticar una predisposicion para cancer de pecho y ovario.
Bale et al. Cancer-associated genodermatoses and familial cancer syndromes with cutaneous manifestations
Lebhard The effects of SNP285 and SNP309 on the expression of MDM2 and p53 in breast cancer.
Building-Room Dr. Zaven Kaprielian Departments of Pathology & Neuroscience Kennedy Building-Room 624 718430-2162; zaven. kaprielianGeinstein. yu. edu The research in my laboratory is aimed at identifying mechanisms that establish stereotyped

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application